Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IFN-beta pharmacogenomics in multiple sclerosis.

Pharmacogenomics - 1 Aug 2010

Vandenbroeck Koen, Urcelay Elena, Comabella Manuel

Abstract excerpt

Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identification and subsequently, implementation in the clinic of biomarkers predictive for individual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Profiling
Share to Glypicans
Share to Interferon Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Sclerosis

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Recombinant Proteins

Source

Identifiers

PMID: 20712530
DOI: 10.2217/pgs.10.108

Genes

GPC5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IFN-beta pharmacogenomics in multiple sclerosis.PMID 20712530Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

United Europeans for development of pharmacogenomics in multiple sclerosis network.Semantic proximity Read ↗

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.Semantic proximity Read ↗

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Glypican 5 is an interferon-beta response gene: a replication study.Semantic proximity Read ↗

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsSemantic proximity Read ↗

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Semantic proximity Read ↗

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.